SCHEMBL3585729

SCHEMBL3585729

NC(=O)N1CCNCC1c1ccc2ccccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.43
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 2/20 0.42
HTR3E A5X5Y0 1/20 0.42
USP2 O75604 1/20 0.42
HTR3B O95264 1/20 0.42
CYP1A2 P05177 1/20 0.42
ADRB1 P08588 1/20 0.42
HTR1A P08908 1/20 0.42
HTR2C P28335 1/20 0.42
SLC6A4 P31645 1/20 0.42
HTR7 P34969 1/20 0.42
HTT P42858 1/20 0.42
HTR3A P46098 1/20 0.42
HTR6 P50406 1/20 0.42
PMP22 Q01453 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5321655 0.78 RIPK1 (0.40) KDM4EHSD17B10HTR2CHTR7DPP4
SCHEMBL6017212 0.78 KDM4E (0.47) CYP3A4KDM4EHSD17B10ALDH1A1MAPK1
SCHEMBL2386164 0.76 DPP4 (0.47) MAPK1HTR2CSLC6A4CA1CA2
SCHEMBL9010420 0.75 KDM4E (0.55) CYP3A4KDM4EHSD17B10ALDH1A1MAPK1
SCHEMBL8168669 0.74 KDM4E (0.43) CYP3A4KDM4EHSD17B10ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL28773228 0.74 DPP4 (0.46) MAPK1HTR2CSLC6A4KMT2ASMN1; SMN2
SCHEMBL16340400 0.74 HTR2C (0.37) KDM4EHTR2CMEN1KMT2ADPP4
SCHEMBL15824978 0.74 TAAR1 (0.43) HTR2CTAAR1
SCHEMBL15737883 0.73 CYP3A4 (0.43) CYP3A4KDM4EHSD17B10ALDH1A1MAPK1
SCHEMBL669693 0.72 HTR2C (0.50) HTR2CDPP4DPP7TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100075953-A1 SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075953-A1 SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS HRH3, HRH4, HRH2 CYP3A4 2305/4885KDM4E 393/4885HSD17B10 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.